Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Omeros Corp OMER

Healthcare
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Recent & Breaking News (NDAQ:OMER)

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Business Wire April 25, 2023

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

Business Wire April 10, 2023

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

Business Wire March 13, 2023

Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank

Business Wire March 10, 2023

Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

Business Wire March 7, 2023

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

Business Wire February 6, 2023

Omeros Corporation Reports Third Quarter 2022 Financial Results

Business Wire November 9, 2022

Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

Business Wire November 8, 2022

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

Business Wire November 4, 2022

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Business Wire November 3, 2022

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

Business Wire October 3, 2022

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Business Wire September 15, 2022

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

Business Wire September 15, 2022

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Business Wire August 17, 2022

Omeros Corporation Reports Second Quarter 2022 Financial Results

Business Wire August 9, 2022

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022

Business Wire August 4, 2022

FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Business Wire July 29, 2022

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Business Wire June 15, 2022

Omeros Corporation Reports First Quarter 2022 Financial Results

Business Wire May 10, 2022

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

Business Wire May 4, 2022